Clinical decision support of therapeutic drug monitoring of phenytoin: Measured versus adjusted phenytoin plasma concentrations

BMC Medical Informatics and Decision Making

Volumn 12, Issue 1, 2012, Pages

  Krasowski, Matthew D ^a   Penrod, Louis E ^b,c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MIAMI CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; PHENYTOIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CHI SQUARE DISTRIBUTION; CHILD; COMPARATIVE STUDY; DECISION SUPPORT SYSTEM; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; INFANT; LABORATORY DIAGNOSIS; MALE; METHODOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG MONITORING; EPILEPSY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LINEAR MODELS; MALE; MIDDLE AGED; PHENYTOIN; SPECIMEN HANDLING;

EID: 84857004430     PISSN: None     EISSN: 14726947     Source Type: Journal    
DOI: 10.1186/1472-6947-12-7     Document Type: Article

References (22)

1. Kohn LT, Corrigan J, Donaldson MS, To err is human: building a safe health system Washington, DC: National Academy Press 2000
2. (U.S.) IoM, Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century Washington, DC: National Academy Press 2001
3. Reducing the frequency of errors in medicine using information technology. Bates DW, Cohen M, Leape LL, Overhage JM, Shabot MM, Sheridan T, J Am Med Inform Assoc 2001 8 299 308 10.1136/jamia.2001.0080299 11418536 (Pubitemid 32641632)
4. Effects of computerized physician order entry on prescribing practices. Teich JM, Merchia PR, Schmiz JL, Kuperman GJ, Spurr CD, Bates DW, Arch Intern Med 2000 160 2741 2747 10.1001/archinte.160.18.2741 11025783
5. Role of computerized physician order entry system in facilitating medication errors. Koppel R, Metlay JP, Cohen A, Abaluck B, Localio AR, Kimmel SE, Strom BL, JAMA 2005 293 1197 1203 10.1001/jama.293.10.1197 15755942 (Pubitemid 40327905)
6. Computerized physician order entry: helpful or harmful? Berger RG, Kichak JP, J Am Med Inform Assoc 2004 11 100 103 14633934 (Pubitemid 38327497)
7. Some unintended consequences of information technology in health care: the nature of patient care information system-related errors. Ash JS, Berg M, Coiera E, J Am Med Inform Assoc 2004 11 104 112 14633936 (Pubitemid 38327498)
8. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Dasgupta A, Clin Chim Acta 2007 377 1 13 10.1016/j.cca.2006.08.026 17026974 (Pubitemid 44920213)
9. Plasma total phenytoin: a possibly misleading test in developing countries. Fedler C, Stewart MJ, Ther Drug Monit 1999 21 15 160
10. The clinical pharmacokinetics of phenytoin. Martin E, Tozer TN, Sheiner LB, Riegelman S, J Pharmacokinet Biopharm 1977 5 579 596 10.1007/BF01059685 599408 (Pubitemid 8253667)
11. Clinically relevant drug interactions with antiepileptic drugs. Perucca E, Br J Clin Pharmacol 2006 61 246 255 10.1111/j.1365-2125.2005.02529.x 16487217 (Pubitemid 43382623)
12. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Patsalos PN, Berry DJ, Bourgeois BFD, Cloyd JC, Glauser TA, Johannessen SI, Tomson T, Perucca E, Epilepsia 2008 49 1239 1276 10.1111/j.1528-1167.2008.01561.x 18397299 (Pubitemid 351991390)
13. Clinical utility of free drug monitoring. Dasgupta A, Clin Chem Lab Med 2002 40 986 993 10.1515/CCLM.2002.172 12476936 (Pubitemid 35356015)
14. Interpatient and intrapatient variability in phenytoin protein binding. Banh HL, Burton ME, Sperling MR, Ther Drug Monit 2002 24 379 385 10.1097/00007691-200206000-00009 12021629 (Pubitemid 34553203)
15. Pharmacokinetic considerations in phenytoin pharmacotherapy: preventing overdoses and underdoses. Profeta LM, Bradbury K, Mehl B, Mt Sinai J Med 1995 62 312 314 7565857
16. Value of therapeutic drug level monitoring and unbound (free) levels. Chan K, Beran RG, Seizure 2008 17 572 575 10.1016/j.seizure.2007.12.007 18262440
17. Predicting unbound phenytoin concentrations in the critically ill neurosurgical patient. Mlynarek ME, Peterson EL, Zarowitz BJ, Ann Pharmacother 1996 30 219 223 8833553 (Pubitemid 26088293)
18. Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation. Monaghan MS, Marx MA, Olsen KM, Turner PD, Bergman KL, Ther Drug Monit 2001 23 263 267 10.1097/00007691-200106000-00014 11360036 (Pubitemid 32476555)
19. Evidence-based implementation of free phenytoin therapeutic drug monitoring. Burt M, Anderson DC, Kloss J, Apple FS, Clin Chem 2000 46 1132 1135 10926893 (Pubitemid 30643315)
20. Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Hong JM, Choi YC, Kim WJ, Yonsei Med J 2009 50 517 520 10.3349/ymj.2009.50.4.517 19718399
21. Effect of ultrafiltrate volume on determination of free phenytoin concentration. McMillin GA, Juenke J, Dasgupta A, Ther Drug Monit 2005 27 630 633 10.1097/01.ftd.0000173373.12569.c7 16175137 (Pubitemid 41437642)
22. Performance characteristics of four free phenytoin immunoassays. Roberts WL, Annesley TM, De BK, Moulton L, Juenke JM, Moyer TP, Ther Drug Monit 2001 23 148 154 10.1097/00007691-200104000-00009 11294515 (Pubitemid 32240142)